Follow-The-Filings

Security · featured owners

KPTI Karyopharm Therapeutics Inc.

COM NEW Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 1.5%
  • $12M
  • 1 add 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 1.5% (David Witzke - Avidity Partners Management) · not free-float ownership

  1. David Witzke add 1.5%
  2. Davidson Kempner Capital Mana... 0.03%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
David Witzke - Avidity Partners Management 2026 Q2 1.5% Add +99.4% 924,487 $9M history
Davidson Kempner Capital Management 2026 Q2 0.03% Hold 300,000 $3M history
Nathan Fischel - Dafna Capital Management exited 2026 Q2 last 2026 Q1 0.06% Exit −0.06 pp 45,800 $255K history

2 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 13 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Jul 28, 2026 Filing Doc
4 Period May 21, 2026 · 6 forms Filing Doc
4 Period May 13, 2026 · 6 forms Filing Doc
4 Period Apr 21, 2026 Filing Doc
4 Period Mar 2, 2026 · 6 forms Filing Doc
4 Period Feb 17, 2026 Filing Doc
4 Period Feb 5, 2026 Filing Doc
4 Period Feb 3, 2026 Filing Doc
4 Period Jan 31, 2026 · 2 forms Filing Doc

Updated 8 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $146.03M $145.24M $146.07M
Net income -$143.1M -$76.42M -$196.04M
Net margin * -98.0% -52.6% -134.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $233.92M $156.49M $103.15M
Total non-current assets * $6.52M $7.93M $5.27M
Total assets $240.44M $164.42M $108.42M
Total current liabilities $69.48M $92.26M $92.06M
Total non-current liabilities * $307.16M $258.17M $309.28M
Total equity -$136.21M -$186.02M -$292.93M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$92.72M -$127.49M -$75.37M
Cash from investing $7.94M $95.47M $43.38M
Cash from financing $1.12M $41.65M $30.05M
Net change in cash -$83.69M $9.62M -$1.92M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders